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L-carnitine is an abundant nutrient in red meat, and dietary intake of L-carnitine can promote cardiovascular 
diseases in humans through microbial production of trimethylamine (TMA) and its subsequent oxidation to 
trimethylamine N-oxide by liver hepatic flavin-containing monooxygenases. Targeting gut microbial production of 
TMA specifically and non-lethal microbial inhibitors in general may then serve as a potential therapeutic 
approach for the treatment of cardiometabolic diseases. A two-component oxygenase/reductase (CntA/B) from 
human microbiota bacterium Acinetobacter baumannii, as well as the alternative enzyme complex YeaW/X from 
E. coli DH10B strain, are two groups of previously reported unusual Rieske-type proteins that cleave carnitine to 
produce TMA, representing an important microbial pathway of TMA production. Despite YeaW/X having 71% 
and 50% sequence identity to CntA and CntB, YeaW/X was found to possess broader substrate usage and 
could produce TMA from either choline or carnitine as substrate. We are therefore pursuing  structural 
investigation of these enzymes to elucidate the  function-structure relationships of these Rieske-type enzymes 
and to decipher the structural basis for broader substrate specificity of YeaW. We have cloned, expressed, and 
purified the CntA/B and Yea W/X enzyme complexes in order to determine crystal structures of apo and 
carnitine-bound forms of both of these enzyme complexes. Such studies should aid in the design of more 
effective inhibitors for the treatment of atherosclerosis. 
 
 
